Dublin, June 13, 2023 (GLOBE NEWSWIRE) -- The "Monoclonal Antibody Discovery and Analysis Market Report 2022-2032" report has been added to ResearchAndMarkets.com's offering.
Overall world revenue surpassed $5.61 billion in 2022
Growing Demand for Monoclonal Antibodies for Cancer Treatments
Monoclonal antibodies have demonstrated anticancer efficacy in a variety of cancers, thus they are not necessary for cancer therapy. Most toxicities, including fever, nausea, fatigue, changes in blood pressure, and bronchospasm, are self-limiting. The efficacy and timeliness of antibody-based diagnostic tests for a variety of disorders have both been enhanced by monoclonal antibodies.
Clinical studies for more than 250 therapeutic monoclonal antibodies are now being conducted. These antibodies are used to treat cancer, autoimmune disorders, infectious diseases, and transplant patients. Inadequate effector functions, immunogenicity, and problems with pharmacokinetics have all been addressed through chimerization and humanization.
As of November 1, 2021, 11 antibody treatments had been given first clearance for usage in either the European Union or the United States: Therapeutic antibodies will unavoidably continue to be a key component of drug research for many years to come. Regardless of the particular path used to produce the next generation of monoclonal antibody therapies, this is true.
What Questions Should You Ask before Buying a Market Research Report?
- How is the monoclonal antibody discovery and analysis market evolving?
- What is driving and restraining the monoclonal antibody discovery and analysis market?
- How will each monoclonal antibody discovery and analysis submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2032?
- How will the market shares for each monoclonal antibody discovery and analysis submarket develop from 2022 to 2032?
- What will be the main driver for the overall market from 2022 to 2032?
- Will leading monoclonal antibody discovery and analysis markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
- How will the market shares of the national markets change by 2032 and which geographical region will lead the market in 2032?
- Who are the leading players and what are their prospects over the forecast period?
- What are the monoclonal antibody discovery and analysis projects for these leading companies?
- How will the industry evolve during the period between 2020 and 2032? What are the implications of monoclonal antibody discovery and analysis projects taking place now and over the next 10 years?
- Is there a greater need for product commercialisation to further scale the monoclonal antibody discovery and analysis market?
- Where is the monoclonal antibody discovery and analysis market heading and how can you ensure you are at the forefront of the market?
- What are the best investment options for new product and service lines?
- What are the key prospects for moving companies into a new growth path and C-suite?
Market Dynamics
Market Driving Factors
- Launches of New Products
- Growing Funding and Healthcare Costs
Market Restraining Factors
- Price Limits
- Pressures for Regulatory Approval
- Induction of Biosimilars
Market Opportunities
- Pandemic Offered Opportunities
- Patent Exclusive Rights
Supply Chain
- Immunotherapy Drug Supply Chain and Logistics Challenges
- Immunotherapies' Vulnerability
- A One-of-a-Kind Starting Point for T-Cell Treatments
- The Supply Chain's Missing Manufacturing Link
- Limited Availability
- Keeping Command of the Immunotherapy Supply Chain
Cold chain
- Agencies Favor Transport Simulation
- Packaging Qualification for Thermal
- Requests for Information Regarding the Schedule of Verification Studies
Recent Trends/ Developments
- The FDA Received an Investigational New Drug (IND) Application for VRDN-002
- Verseau Therapeutics, Inc. Reported on January 4, 2022, FDA Approval
- A Veterinary mAb Receives FDA Approval for the First Time
- Two Antibody Therapies Are in Seagen's Clinical Study Queue.
- Spirea Raises £2.4 Million to Create Cancer-Specific Antibody Drug Conjugates
- Exelixis, Inc. of California and BioInvent International AB of Sweden partner to Create New Antibodies for Immuno-oncology Treatments
Leading companies and the potential for market growth
- AbbVie Inc.
- Amgen Inc.
- Amneal Pharmaceutical LLC
- AstraZeneca
- Bayer AG
- BIOGEN
- Bristol- Myers Squibb company
- Eisai Co. Ltd
- Eli Lilly and Company
- F. Hoffman-La Roche Ltd.
- GlaxoSmithKline plc
- Johnson & Johnson Ltd.
- Lupin Limited
- Viatris Inc.
- Novartis AG
- Pfizer Inc.
- Regeneron Pharmaceuticals Inc.
- Sanofi S.A.
- Teva Pharmaceutical Industries Ltd.
- Zydus Lifesciences Limited
Segments Covered in the Report
Business Type
- Instruments Manufacturing
- Services & Solutions
- Ancillary Kits
Application
- Therapeutic Antibody Discovery
- Critical Reagent Antibody Discovery
- Biomarker and Diagnostic Antibody Discovery
- Research Antibody Discovery
Platform
- Hybridoma
- Humanization
- Phage Display
- Yeast Display
- Transgenic Rodents
Type
- Antigen Development
- Monoclonal Antibody Discovery
- Monoclonal Antibody Manufacturing
- Polyclonal Antibodies
- Label-free Kinetics Analysis
- Cell Banking
North America
- U.S.
- Canada
Europe
- Germany
- Spain
- United Kingdom
- France
- Italy
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia Pacific
Middle East & Africa
- Turkey
- Saudi Arabia
- South Africa
- Rest of Middle East & Africa
Latin America
- Brazil
- Mexico
- Rest of Latin America
For more information about this report visit https://www.researchandmarkets.com/r/xi9i4r
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
